Navigation Links
Roche Selects Thomson Reuters to Transform the Management of Its Intellectual Property Assets

BINGHAM FARMS, Mich., Sept. 5, 2012 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced that The Roche Group, a leading provider of pharmaceutical and diagnostic products and services, has selected Thomson IP Manager® to manage the organization's expanding international patent portfolio. Thomson IP Manager, a premier intellectual asset management (IAM) software solution, will improve company-wide IP work processes and collaboration across the organization.

Headquartered in Switzerland, Roche is a research-focused company, discovering, developing and providing innovative diagnostic and therapeutic products and services to patients and healthcare professionals worldwide. With twelve patent group sites in Asia, Europe and the United States, Roche needs a global solution that will allow it to efficiently and effectively manage its valuable IP asset portfolio, which grows by nearly 500 rights annually.

Roche initiated a global patent group project, taking a democratic approach as part of its selection process. Patent and law professionals evaluated several high-potential IAM software solutions before making the decision to use Thomson IP Manager.

"Having been involved in various mergers and acquisitions, which culminated with the Genentech merger in 2009, IP asset management has been a challenge within our organization. Different business units around the world were using different systems to manage our patent portfolio," said Karin Bruehlmann, Head of Controlling, IT & Services Group Patents, The Roche Group. "Thomson IP Manager is a modern, global solution that will help us minimize our current workload by reducing manual processes and enabling effective collaboration between departments to ensure our critical innovation assets remain protected."

According to Mrs. Bruehlmann, Roche also will utilize the Thomson IP Manager integrated Data Validation Service to proactively identify and correct data discrepancies in their patent portfolio, comparing data against the Thomson Reuters Global Patent Collection. This comprehensive database comprises over 76 million patents for more than 70 issuing authorities. It ensures errors that could affect critical prosecution and maintenance dates can be quickly caught and fixed, reducing the risk of lost rights and costly delays.

"We are pleased to partner with Roche to provide unified workflow processes for the IP team that will accelerate the time from idea to commercialization," said Cynthia Murphy, senior vice president and general manager, Innovation and Asset Management, Thomson Reuters. "As a leading provider of intellectual asset management solutions, we are committed to supporting Roche in eliminating the structural and geographical boundaries that exist due to the global and acquisitive nature of their business."

For more information visit:

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. Roche has 80,000 employees worldwide.

About Thomson IP Management Services 
Businesses and law firms at the forefront of intellectual asset management partner with Thomson IP Management Services. From ideation through prosecution and commercialization, Thomson IP Management Services helps clients maximize the value of their portfolio, keep it aligned with their business strategy and drive global competitiveness. Their solutions integrate state-of-the-art portfolio management technology, comprehensive IP payment services, IP management consulting and a world-class IP rules collection to provide unparalleled support of clients' patents, trademarks, licenses and other intellectual assets.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. For more information, go to

SOURCE Thomson Reuters
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. Rochester Medical Introduces Magic3® Coude Tip Hydrophilic Intermittent Catheter
3. Roche announces FDA approval of HIV viral load test
4. FDA clears Accu-Chek Combo system - Roches new interactive insulin pump system for people with diabetes
5. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
6. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
7. Rochester Medical Reports Third Quarter Results
8. Roche receives FDA clearance for herpes simplex virus type 1 and 2 tests
9. Angeion Selects Hendrik Struik for Board of Directors
10. PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor
11. Valeritas Inc. Selects dLifes New Diabetes Patient Engagement Solution For Valeritas V-go Disposable Insulin Delivery Device
Post Your Comments:
(Date:12/1/2015)... --> --> ... Acid Labeling Market by Product (Reagents & Kits, Services), ... Vitro Transcription, Reverse Transcription, End Labeling), by Region - ... market is expected to reach USD 1,925.7 Million by ... a CAGR of 8.65%. Browse 77 market ...
(Date:12/1/2015)... 1, 2015 Building on its 25-year ... Johnson (NYSE: JNJ ) today announced four ... to significantly reduce the burden of HIV incidence, ... percent of new HIV infections among adolescents in ... Day, these new initiatives include collaborations with the ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... ) has announced the addition of ... Testing Market: Campylobacter, Cryptosporidium, E. Coli, ... Yersinia" report to their offering. ... announced the addition of the ...
Breaking Medicine Technology:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... radiographic technicians must mark the film for accurate interpretation by the radiologist. The ... Fortunately, an inventor from Sacramento, Calif., has found a way to alleviate this ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... (BHCOE) today announced that the organization has awarded Education and Developmental Therapies (EDT), ... Distinguished Award. The award celebrates exceptional special needs providers that excel in synthesizing ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Lutronic, a leading ... Clarity, the latest addition to the devices for sale in the United States. ... Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 ... semi-finalists to head to Las Vegas for CES 2016, the world’s largest Consumer Electronic ... Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Nurotron Biotechnology Co., ... its largest order to date. , The order will be from the China ... Venus Cochlear Implant System is an effective solution for children and adults suffering from ...
Breaking Medicine News(10 mins):